Business Standard
Tuesday, Nov 24, 2009
 
drived banner
drived banner
  Advanced Search
Feedback | RSS
Content Guide
Follow us on  
||Companies & Industry||||||| 
 Section Home | News Now | Today's Paper | Q&A | People in the News | Industry News | Features | The Compass | Research & Analysis | Opinion | Corporate Results
Home > Companies & Industry Live Markets | Smart Portfolios II
  Search:

Aurobindo gets nod to market 2 more products in S Africa
BS Reporter / Hyderabad October 29, 2009, 17:57 IST

Aurobindo Pharma Limited, a Hyderabad-based manufacturer of generic pharmaceuticals and active pharmaceutical ingredients (APIs), has received approval from the Medicines Control Council (MMC) to manufacture and market two more products in South Africa.

BSE | NSE
Price  
 
 
Related Stories
News Now
-Glenmark Pharma Q2 net dips 31% to Rs 81 cr
-Natco to make 10 mn strips of generic Tamiflu available by Oct
-Aurobindo gets US FDA nod
-Aurobindo Pharma receives Swissmedic approval
-Aurobindo Pharma receives Swissmedic approval for cefepime for injection
-Aurobindo Pharma up 2.4%

These are Auro-Ampicilin 500mg and 100mg injections and Auropidone 0.5 mg tablets that fall under the anti-infective and central nervous system categories respectively.

With these, Aurobindo now has 37 products approved by the MCC, the company said in a press release on Thursday.

Aurobindo’s scrip is currently trading at Rs 771.95 on the BSE, down 5.72 per cent as against the previous close of Rs 818.80.

Arrow Other Stories     
- Markets slip deeper into red
- NEWSALERT: Liberhan Commission report tabled in LS
- Agni-II fails to meet mission parameters
- BSE to roll out websites in regional languages soon
- UK credit information major to expand to India
More  
  Read Business news in 
  Get financial advisory and solutions for your projects
  Holidays starting at a delightful EMI of Rs 3481
  Switch on and say hello to Monday morning !
  Your dream home can now be a reality.
  Visit Fortis for a preventive health check-up & get a 20% discount.
  Follow the ups and downs of your investments. Try our new Portfolio Tracker
  Kolkata Dock \ Freight contract for the British Gurkhas Nepal
  Find how Midsize Businesses use ERP to gain competitive advantage
  Trading in Forex is now as easy as 1-2-3
  Discover an economical and cost effective way to market your products and services
  Giftwithlove.com: Same day delivery of Flowers and Cakes to India
  Download the E-book on the Future of Business Intelligence
  Learn Best Practices for improving customer satisfaction
  Know your customers better... download the free e-book on CRM
Share this Story  
 
 
   Discussion Board / User Comments    
Display Name  Email-Id  
Post your comment
Most Popular
Read
E-Mailed
Commented
   
- Search for Tejas engine nears its end
- Infosys BPO chief quits; to join HDFC Standard Life
- Tea with BS: Amitabh Bachchan
- Sebi showcause back to haunt RIL
- Mahindra's Gio logic
 
 More  
BS Poll
Cast Your Vote
 
   
 
Should educational institutions be allowed to approach the capital market?
  Yes  No
Submit

  Hot Searches  
 
Amitabh Bachchan | N Chandrasekaran | Swine Flu | Mukesh Ambani | Anil Ambani | TCS | Infosys |  Air India |  Duronto |  Pranab Mukherjee | Sonia Gandhi | Congress | Rahul Gandhi |  Bigg Boss |  New Pension Scheme |  Service tax |  Excise duty |  Sebi | Tech Mahindra |  Ramalinga Raju |  Satyam |  Reliance  |  RBI |  GDP |  Gold |  Ratan Tata |  ICICI |  |  B-School | DLF  Sensex |  Tax calculator | Home Loan  | Bollywood | Personal Finance |  inflation | oil prices |  World Bank | Reliance Infratel |  HDFC |  Barack Obama  
 
  Member Area Write to the Editor RSS Archives Advanced Search
  Subscribe to BS print product BS e-paper Newsletter Portfolio Tracker
  BS Products BS Hindi BS Motoring
FOR HOT PRODUCTS
BS Bazaar.com
Home | Markets & Investing | Companies & Industry | Banking & Finance | Economy & Policy | Opinion
Life & Leisure | Management & Marketing | Tech World
About Us | Partner With Us | Code of Conduct | Careers | Advertise with us| Terms & Conditions | Disclaimer | Site Map | Contact Us | Feedback